NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular ...
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer Patients in the NuTide:302 Study Achieved …